Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$41.27|
|52 Week High||US$25.31|
|52 Week Low||US$141.01|
|1 Month Change||-5.82%|
|3 Month Change||13.26%|
|1 Year Change||15.38%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||194.37%|
Recent News & Updates
We're Not Worried About Vir Biotechnology's (NASDAQ:VIR) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
|VIR||US Biotechs||US Market|
Return vs Industry: VIR matched the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: VIR underperformed the US Market which returned 30.3% over the past year.
Stable Share Price: VIR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: VIR's weekly volatility has decreased from 17% to 10% over the past year, but is still higher than 75% of US stocks.
About the Company
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd.
Vir Biotechnology Fundamentals Summary
|VIR fundamental statistics|
Is VIR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VIR income statement (TTM)|
|Cost of Revenue||US$344.89m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Nov 04, 2021
|Earnings per share (EPS)||-2.28|
|Net Profit Margin||-162.74%|
How did VIR perform over the long term?See historical performance and comparison
Is Vir Biotechnology undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate VIR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate VIR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: VIR is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: VIR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VIR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VIR is overvalued based on its PB Ratio (7.3x) compared to the US Biotechs industry average (2.9x).
How is Vir Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VIR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VIR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VIR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VIR's revenue (22% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: VIR's revenue (22% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VIR is forecast to be unprofitable in 3 years.
How has Vir Biotechnology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VIR is currently unprofitable.
Growing Profit Margin: VIR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VIR is unprofitable, and losses have increased over the past 5 years at a rate of 43.1% per year.
Accelerating Growth: Unable to compare VIR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VIR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: VIR has a negative Return on Equity (-40.33%), as it is currently unprofitable.
How is Vir Biotechnology's financial position?
Financial Position Analysis
Short Term Liabilities: VIR's short term assets ($862.3M) exceed its short term liabilities ($146.0M).
Long Term Liabilities: VIR's short term assets ($862.3M) exceed its long term liabilities ($174.2M).
Debt to Equity History and Analysis
Debt Level: VIR is debt free.
Reducing Debt: VIR had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VIR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: VIR has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 20% each year.
What is Vir Biotechnology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VIR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VIR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VIR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VIR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VIR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
George Scangos (73 yo)
Dr. George A. Scangos, Ph D., serves as the Chief Executive Officer, President and Director of Vir Biotechnology, Inc. since January 2017. Dr. Scangos served as the Chief Executive Officer of Biogen Idec L...
CEO Compensation Analysis
Compensation vs Market: George's total compensation ($USD994.88K) is below average for companies of similar size in the US market ($USD6.33M).
Compensation vs Earnings: George's compensation has been consistent with company performance over the past year.
Experienced Management: VIR's management team is considered experienced (3.8 years average tenure).
Experienced Board: VIR's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.8%.
Vir Biotechnology, Inc.'s employee growth, exchange listings and data sources
- Name: Vir Biotechnology, Inc.
- Ticker: VIR
- Exchange: NasdaqGS
- Founded: 2016
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$5.390b
- Shares outstanding: 130.61m
- Website: https://www.vir.bio
Number of Employees
- Vir Biotechnology, Inc.
- 499 Illinois Street
- Suite 500
- San Francisco
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/25 23:24|
|End of Day Share Price||2021/10/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.